Dr. Raghu Ramachandra is the Associate Director of Exploratory Pharmacology for the at Sanford Burnham Prebys. He is also the Lead Scientist at the ADME/PK core facility at Conrad Prebys Center for Chemical Genomics.
Prior to joining Sanford Burnham Prebys, Raghu was the Executive Director and head of Scientific Operations at Galore Tx Pharmaceuticals Private Limited, a drug discovery startup based in Bangalore India. He led Galore Tx to be a revenue generating biotech while also heading in vitro, in vivo pharmacology, ADME and in vivo DMPK teams in support of several discovery projects spanning oncology, inflammation, and infectious diseases.
Prior to co-founding Galore Tx, he worked with Aurigene Discovery Technologies Limited (a 100% subsidiary of Dr Reddy’s Laboratories, NYSE: RDY) in Bangalore, India where he established several in vivo disease models for evaluating efficacy and safety of small molecules and peptides.
Postdoctoral Training: Host-Pathogen Interactions, City of Hope National Medical Center
2008: PhD, Animal and Food Science, West Virginia University
At the Institute, he has established an ADME/PK core facility to complement the small molecule discovery platforms already in existence. He is involved in strategic planning, and in the coordination of effort between the project teams of the Center and its collaborators to execute projects on schedule and on budget.
US11497735B2
Conjoint therapies for immunomodulation
Inventors: Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Raghuveer K. Ramachandra, Adam S. Lazorchak, Timothy L. Wyant
Sasikumar PG, Sudarshan NS, Adurthi S, Ramachandra RK, Samiulla DS, Lakshminarasimhan A, Ramanathan A, Chandrasekhar T, Dhudashiya AA, Talapati SR, Gowda N, Palakolanu S, Mani J, Srinivasrao B, Joseph D, Kumar N, Nair R, Atreya HS, Gowda N, Ramachandra M
Commun Biol 2021 Jun 8 ;4(1):699Sasikumar PG, Ramachandra RK, Adurthi S, Dhudashiya AA, Vadlamani S, Vemula K, Vunnum S, Satyam LK, Samiulla DS, Subbarao K, Nair R, Shrimali R, Gowda N, Ramachandra M
Mol Cancer Ther 2019 Jun ;18(6):1081-1091Holmström TH, Moilanen AM, Ikonen T, Björkman ML, Linnanen T, Wohlfahrt G, Karlsson S, Oksala R, Korjamo T, Samajdar S, Rajagopalan S, Chelur S, Narayanan K, Ramachandra RK, Mani J, Nair R, Gowda N, Anthony T, Dhodheri S, Mukherjee S, Ujjinamatada RK, Srinivas N, Ramachandra M, Kallio PJ
Mol Cancer Ther 2019 Jan ;18(1):28-38Ramachandra RK, Salem M, Gahr S, Rexroad CE 3rd, Yao J
BMC Dev Biol 2008 Apr 15 ;8():41